Orforglipron and Heart Events in People With Heart Artery Disease or Chronic Kidney Disease
Tests orforglipron against placebo for heart problems in adults with artery or kidney disease.
Plain-language title generated from the registry record
Registry title: A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Key facts
- Where
- Aracaju, Belém, Belo Horizonte, Blumenau, Bragança Paulista, Brasília, Campinas, Campo Grande, Canoas, Curitiba, Fortaleza, Jaú, Marília, Niterói, Porto Alegre, Rio de Janeiro, Salvador, São Bernardo do Campo, São José do Rio Preto, São José dos Campos, São Paulo, Tatuí, Vitória, and Votuporanga, BrazilSee the 34 sites
- Phase
- Phase 3
Where in Brazil
- Centro de Pesquisa Clinica do CoracaoAracaju, BrazilTaking people
- Hospital Universitário João de Barros BarretoBelém, BrazilTaking people
- NUPEC - CardioBelo Horizonte, BrazilTaking people
- University Center of Belo Horizonte - Campus BuritisBelo Horizonte, BrazilTaking people
- AngioKormann BlumenauBlumenau, BrazilTaking people
- Hospital Universitário São Francisco de Assis - Bragança PaulistaBragança Paulista, BrazilTaking people
- Chronos Pesquisa ClínicaBrasília, BrazilTaking people
- Centro de Pesquisa Sao LucasCampinas, BrazilTaking people
- Instituto de Pesquisa Clínica de CampinasCampinas, BrazilTaking people
- Loema Instituto de Pesquisa ClinicaCampinas, BrazilTaking people
- Hospital Universitário Maria Aparecida PedrossianCampo Grande, BrazilTaking people
- Hospital UniversitárioCanoas, BrazilTaking people
- Cline Research CenterCuritiba, BrazilTaking people
- Instituto de Ensino e Pesquisa Clinica do CearaFortaleza, BrazilTaking people
- Private Practice - Dr.Miguel N. HissaFortaleza, BrazilTaking people
- CECIP - Centro de Estudos do Interior PaulistaJaú, BrazilTaking people
- Centro de Pesquisa Clínica de Marília - CPCLIMMarília, BrazilTaking people
- CHN - Complexo Hospitalar de NiteróiNiterói, BrazilTaking people
- Instituto de Cardiologia do Rio Grande do SulPorto Alegre, BrazilTaking people
- Nucleo de Pesquisa Clínica do Rio Grande do SulPorto Alegre, BrazilTaking people
- IBPClin - Instituto Brasil de Pesquisa ClínicaRio de Janeiro, BrazilTaking people
- Ruschel Medicina e Pesquisa ClínicaRio de Janeiro, BrazilTaking people
- Hospital Ana Nery (HAN) - SalvadorSalvador, BrazilTaking people
- Obras Sociais Irma DulceSalvador, BrazilTaking people
- Centro Multidisciplinar de Estudos ClinicosSão Bernardo do Campo, BrazilTaking people
- Fundacao Faculdade Regional de Medicina de Sao Jose do Rio PretoSão José do Rio Preto, BrazilTaking people
- Centro Internacional de Pesquisa Clínica (CIPES)São José dos Campos, BrazilTaking people
- CEPIC - Centro Paulista de Investigação ClínicaSão Paulo, BrazilTaking people
- CPCLINSão Paulo, BrazilTaking people
- CPHosp Medicina, Ensino e Pesquisa (CPQuali)São Paulo, BrazilTaking people
- Hospital das Clinicas FMUSPSão Paulo, BrazilTaking people
- Instituto de Molestias Cardiovasculares de TatuiTatuí, BrazilTaking people
- CEDOESVitória, BrazilTaking people
- Integral Pesquisa e EnsinoVotuporanga, BrazilTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07241390EU 2025-523123-22-00
- Record updated
- 4 November 2026
- Original description
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.Read full original descriptionShow less
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Orforglipron on the Incidence of Major Adverse Cardiovascular Events in Participants With Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.
Inclusion: Have established ASCVD and/or CKD.
Exclusion: Have had a major heart condition within 60 days prior to screening; Have type 1 diabetes; Have New York Heart Association Functional Classification Class IV heart failure.